Clinical Trial Update: Canagliflozin and Myocardial Fibrosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating canagliflozin for myocardial fibrosis in people with Type 2 diabetes mellitus and cardiovascular disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Type 2 Diabetes, Cardiovascular Risk | Phase 4 | Status: COMPLETED